Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
EP Vantage MedTech Half-Year Review 2013
The latest report from EP Vantage is a review of the medical device and diagnostic sector’s performance in the first half of 2013.
This extensively researched report, based on EvaluateMedTech market intelligence, identifies some of the key trends that defined the industry in the six months from January to June 2013.
The report reveals that despite most large-cap medtech companies seeing reliable share price growth, 2013 has been a disappointing year so far for the medical technology industry. Not only did the sector experience a steep decline in FDA-approved medical technologies, the low number of completed mergers and acquisitions puts 2013 on track to be the most disappointing year for M&A activity in a decade.
Key findings of the report include:
- The large-cap companies seeing the greatest share price rises have invested in fast-growing areas such as next-generation sequencing, renal denervation and companion diagnostics.
- First-time premarket approvals (PMAs) were down 47 percent since 2012 with the FDA granting only nine PMAs compared to the 19 issued in the first half of 2012.
- Cardiology and in vitro diagnostics (IVD) were the most represented therapeutic categories for first-time PMAs.
- Thermo Fisher Scientific leads the field of large-cap share price rises due in large part to its $13.6 billion acquisition of Life Technologies, the biggest medtech purchase the sector has seen this year.
EP Vantage Pharma Half-Year Review 2013
EP Vantage 2012 Year in Review